

Supplementary Table S1. Baseline characteristics by MAFLD


Characteristics	Non-MAFLD	MAFLD	P value
N (%)	3,642 (64.39)	2,014 (35.61)	
Age, <i>n</i> (year)	60.12 ± 7.08	60.35 ± 6.86	0.2562
Male, <i>n</i> (%)	1,290 (35.42)	719 (35.70)	0.8331
BMI (kg/m ²)	23.94 ± 4.51	27.04 ± 6.00	< 0.0001*
Waist circumference (cm)	80.54 ± 9.42	88.56 ± 9.44	< 0.0001*
Diabetes, <i>n</i> (%)	626 (17.19)	791 (39.28)	< 0.0001*
HbA1c, <i>n</i> (%)	5.56 ± 0.66	5.95 ± 0.94	< 0.0001*
FPG, mmol/L	5.88 ± 1.23	6.53 ± 1.75	< 0.0001*
2h PG, mmol/L	8.03 ± 3.29	10.33 ± 4.13	< 0.0001*
HOMA-IR	1.53 (1.09-2.16)	2.73 (2.00-3.92)	< 0.0001*
SBP, mmHg	131.30 ± 16.88	137.97 ± 15.96	< 0.0001*
DBP, mmHg	75.79 ± 9.47	78.28 ± 9.38	< 0.0001*
TC, mmol/L	5.23 ± 0.97	5.39 ± 1.10	< 0.0001*
TG, mmol/L	1.33 (0.98-1.84)	1.97 (1.46-2.82)	< 0.0001*
HDL-C, mmol/L	1.39 ± 0.31	1.24 ± 0.26	< 0.0001*
LDL-C, mmol/L	3.55 ± 0.78	3.72 ± 0.81	< 0.0001*
ALT, IU/L	18 (14-24)	26 (20-38)	< 0.0001*
AST, IU/L	24 (21-29)	27 (23-33)	< 0.0001*
Albumin, g/L	46.14 ± 2.52	46.54 ± 2.55	< 0.0001*
Platelet, × 10 ⁹ /L	191.96 ± 63.11	202.75 ± 54.57	< 0.0001*
NFS	-1.21 ± 1.15	-1.13 ± 1.17	0.0173*
Current smoker, <i>n</i> (%)	631 (17.33)	368 (18.27)	0.3715
Current drinker, <i>n</i> (%)	310 (8.87)	184 (9.44)	0.4856
High school and above, <i>n</i> (%)	760 (20.94)	398 (19.92)	0.3666
Moderate and vigorous physical activity, <i>n</i> (%)	366 (10.05)	255 (12.66)	0.0026*

Note. Data were means ± SD or medians (interquartile range) for skewed variables or proportions for categorical variables. *Statistically significant. MAFLD, metabolic dysfunction-associated fatty liver disease; BMI, body mass index; FPG, fasting plasma glucose; 2h PG, 2h plasma glucose; HOMA-IR, homeostasis model assessment of insulin resistance; SBP, systolic blood pressure; DBP, diastolic blood pressure; TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; ALT, alanine transaminase; AST, aspartate transaminase; NFS, NAFLD fibrosis score.

Supplementary Table S2. ORs (95% CIs) for MAFLD according to famine exposure in early life using the younger and older groups as reference

Model	Nonexposed (1963–1970) + Adolescent-exposed (1945–1948)	Fetal-exposed (1959–1962)	Childhood-exposed (1955–1958)
Whole cohort Case/Total	574/1,590	291/788	356/1,037
Model 1	1.00 (ref)	1.04 (0.87–1.24)	0.93 (0.79–1.09)
Model 2	1.00 (ref)	1.11 (0.92–1.33)	0.94 (0.80–1.11)
Model 3	1.00 (ref)	1.13 (0.93–1.37)	0.95 (0.80–1.13)
Men			
Case/Total	243/591	112/272	118/349
Model 1	1.00 (ref)	1.00 (0.75–1.34)	0.73 (0.56–0.96)
Model 2	1.00 (ref)	0.86 (0.64–1.17)	0.71 (0.54–0.94)
Model 3	1.00 (ref)	0.83 (0.61–1.13)	0.71 (0.54–0.95)
Women			
Case/Total	331/999	179/516	238/688
Model 1	1.00 (ref)	1.07 (0.86–1.34)	1.07 (0.87–1.31)
Model 2	1.00 (ref)	1.32 (1.04–1.68)	1.12 (0.91–1.38)
Model 3	1.00 (ref)	1.39 (1.09–1.79)	1.14 (0.92–1.41)

Note. Model 1: unadjusted. Model 2: adjusted for age, sex. Model 3: adjusted for sex, age, smoking, alcohol consumption, education and physical activity. MAFLD, metabolic dysfunction–associated fatty liver disease.

**Supplementary Figure S1.** Flow chart of the sampling frame and participants in the famine exposure study.